Keros Therapeutics doses first patient in Phase 2 rinvatercept trial; initial data expected H1 2027

Keros Therapeutics dosed the first patient in its Phase 2 trial of rinvatercept for Duchenne muscular dystrophy and expects initial data in the first half of 2027.Key Highlights:Original SEC Filing: Keros Therapeutics, Inc. [ KROS ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain…